MiNK Therapeutics (INKT) Stock Analysis: AI Score & Alternative Data
INKT alt-data: sentiment climbing, web traffic lagging
Is MiNK Therapeutics a buy right now? The alternative data says hold. This INKT stock analysis is built on the 25+ alternative data signals AltIndex tracks on MiNK Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 52/100: a Hold. The stock trades at $9.41 with a $51M market cap.
The bullish side of the 90-day ledger: sentiment up 51.5% to 100/100. The drag: web traffic down 44.3% to 2K monthly visits. That tension is what keeps the score mid-range.
INKT’s broader alt-data profile also covers headcount (31 employees, according to LinkedIn). Every signal links to its own page with full history, the INKT technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on INKT is just below.
MiNK Therapeutics AI Stock Analysis
MiNK Therapeutics is a biotechnology company specializing in cellular immunotherapy for treating cancers and other diseases. Known for its innovative approach, MiNK aims to revolutionize patient outcomes through proprietary platforms that leverage the body's natural immune response to target and eliminate cancer cells.
Analysis generated October 1, 2026.
Recent MiNK Therapeutics Stock Alerts
|
MiNK Therapeutics | October 16 Insider Alert: Buell Jennifer is selling shares |
|
MiNK Therapeutics | September 10 Price is up by 6.6% in the last 24h. |
|
MiNK Therapeutics | September 9 Price is up by 6.3% in the last 24h. |
|
MiNK Therapeutics | August 19 Price is down by -7.8% in the last 24h. |
MiNK Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 2K | 44.3% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 31 | 0% | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 100 | 51.5% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 0% | |
| Stocktwits Mentions | 6 | 45.5% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 2K | 0% |
About MiNK Therapeutics (INKT)
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, ready-to-use, invariant natural killer T-cell therapies for treating cancer and other immune-mediated diseases. The company is headquartered in New York, New York.
| Price | $9.41 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $51M |
| Year Range | $9 – $15 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest MiNK Therapeutics News
View more →
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders MeetingJune 3 - GlobeNewswire |
|
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical IllnessMay 28 - GlobeNewswire |
|
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology CommunicationsMay 20 - GlobeNewswire |
|
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical ValidationMay 15 - GlobeNewswire |
|
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical IllnessMay 14 - GlobeNewswire |
See MiNK Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for INKT, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEMiNK Therapeutics Earnings & Financial Performance
View all earnings →MiNK Therapeutics Insider Trading Activity
View all →| Buell Jennifer filed to sell 74,195 shares at $0.0. Oct 12 '26 |
| Ryan Barbara filed to sell 22,969 shares at $0.0. Jun 4 '26 |
| Ryan Barbara filed to sell 21,969 shares at $0.0. Jun 4 '26 |
| Ryan Barbara filed to sell 21,406 shares at $0.0. Mar 10 '26 |
| Ryan Barbara filed to sell 20,406 shares at $0.0. Mar 10 '26 |
MiNK Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to MiNK Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
DarioHealthDRIO |
$4.82 6.0% | $50M | 35 |
 |
LeonaBioLONA |
$5.20 1.7% | $50M | 48 |
 |
NovaBay PharmaceuticalsNBY |
$1.95 22.6% | $52M | 40 |
 |
Kalaris TherapeuticsKLRS |
$2.00 8.7% | $52M | 55 |
 |
Werewolf TherapeuticsHOWL |
$0.98 1.7% | $48M | 45 |
Explore MiNK Therapeutics Data
Frequently Asked Questions: MiNK Therapeutics (INKT)
MiNK Therapeutics has an AltIndex AI Score of 52/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
52/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of MiNK Therapeutics (INKT) stock is $9.41 with a market cap of $51M.
As of today, MiNK Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest MiNK Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the MiNK Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The INKT stock price chart above shows MiNK Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full MiNK Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to MiNK Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
